Budd-Chiari syndrome with fresh inferior vena cava thrombosis: agitation thrombolysis and balloon dilation.

BACKGROUND: To evaluate retrospectively our initial clinical experience of agitation thrombolysis and balloon dilation in the treatment of Budd-Chiari syndrome (BCS) in patients with fresh inferior vena cava (IVC) thrombosis. PATIENTS AND METHODS: Between August 2004 and March 2009, a total of 12 BCS patients with fresh IVC thrombosis were treated with agitation thrombolysis and balloon dilation. Color Doppler ultrasound results, as well as mortality, morbidity, and the clinical outcomes were evaluated immediately after the treatment and at one week and 1, 3, 6, 12 months after the procedure and then annually thereafter. RESULTS: Agitation thrombolysis and balloon dilation were technically successful in all patients, without immediate procedural complications. The inferior vena cavagrams after the procedure demonstrated complete resolution of the IVC thrombi without pulmonary embolism and full patency of the obstructed IVC. Thirty-day mortality was nil. Clinical success was observed in all patients respectively one month after the procedure. As of February 2010, the mean (± SD) follow-up period for the color Doppler ultrasound procedure was 21.7 ± 8.9 months (range, 12 - 32 months). All patients showed complete patency of the treated IVC without thrombosis, restenosis, or reobstruction, and all patients are alive with resolution of the symptoms at the time of this report. CONCLUSIONS: Our preliminary results suggest that agitation thrombolysis and balloon dilation may be a feasible approach for patients with BCS and fresh IVC thrombosis. However, larger studies are warranted to confirm these results.

Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.

PURPOSE: This study was undertaken to evaluate the safety and feasibility of thrombolytic urokinase treatment after predilation in patients with Budd-Chiari syndrome (BCS) with chronic inferior vena cava (IVC) thrombosis. MATERIALS AND METHODS: Between December 2006 and September 2009, 13 consecutive BCS patients with chronic IVC thrombosis were treated with continuous urokinase infusion after predilation and subsequent (i.e. after thrombus resolution) IVC dilation with a 30-mm dilator. The procedural technical and angiographic, and ultrasonic results, as well as mortality, morbidity and the final clinical outcome, were evaluated immediately after the treatment or at 1 week and 1, 3, 6 and 12 months and then annually thereafter. RESULTS: The immediate and long-term procedural technical outcome was successful in all patients. Follow-up inferior vena cavagrams demonstrated complete resolution of the chronic IVC thrombi and full IVC patency, without occurrence of pulmonary embolism at any time during the study. Colour-Doppler ultrasound (US) follow-up for 16.92 months (± 12.04) showed full patency of the IVC, without thrombosis, restenosis or reobstruction, in all patients and resolution of all clinical symptoms. All patients were alive at the time of this report. CONCLUSIONS: Our preliminary results indicate that thrombolysis with continuous infusion of urokinase after predilation is a safe and feasible approach for treating BCS patients with chronic IVC thrombosis.

Outcome of a retrieval stent filter and 30mm balloon dilator for patients with Budd-Chiari syndrome and chronic inferior vena cava thrombosis: a prospective pilot study.

AIM: To evaluate the mid-term safety and efficacy of a retrieval stent filter and 30mm balloon dilator in the treatment of Budd-Chiari syndrome (BCS) patients with chronic inferior vena cava (IVC) thrombosis. MATERIALS AND METHODS: Twenty-three consecutive patients with BCS and chronic IVC thrombosis were treated with a retrieval stent filter and a 30mm balloon dilator, and subsequently underwent color Doppler ultrasound follow-up at our hospital. Data relating to the technical success, angiographic and ultrasound results, mortality, morbidity, and final clinical outcome were collected retrospectively and follow-ups were performed 1, 3, 6, and 12 months after placement of the stent, and annually thereafter. RESULTS: Stent filter placement and balloon dilation were technically successful in all patients, with no procedure-related complications. Removal of the stent filter was technically successful in 22 of 23 attempts, yielding a technical successful rate of 95.7% (95% confidence intervals (CI): 87%, 105%). Inferior vena cavagrams performed immediately before stent removal demonstrated that the IVC thrombus had completely resolved in all patients without pulmonary embolism. The mean primary patency rate 3, 6, 12, and 24 months after venoplasty was 0.91 (95% CI: 0.79-1.04), 0.87 (95% CI: 0.72-1.02), 0.87 (95% CI: 0.72-1.02), and 0.87 (95% CI: 0.72-1.02), respectively. The secondary patency rates were 1.00 throughout the follow-up period. All patients are alive with resolution of the symptoms at the time of this report. CONCLUSIONS: The preliminary results indicate that the retrieval stent filter and 30mm balloon dilator are a safe and effective treatment for BCS patients with chronic IVC thrombosis.